Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S

First Page		Document Content
Date: 2014-11-03 11:26:22 Medicine HIV/AIDS Cyclopropanes Integrase inhibitors Amides Lamivudine Zidovudine Antiretroviral drug GlaxoSmithKline Chemistry Organic chemistry Organofluorides		Shionogi-ViiV Healthcare LLC Presents Positive Data on Investigational Once-Daily Integrase Inhibitor at International AIDS Conference Positive Antiviral Responses Demonstrated in Interim 16 Week Analysis from SPRING-1 S Add to Reading List Source URL: shionogi616.tew-staging.com Download Document from Source Website File Size: 66,50 KB Share Document on Facebook

	Communication pubs.acs.org/JACS Highly Diastereo- and Enantioselective Synthesis of TriﬂuoromethylSubstituted Cyclopropanes via Myoglobin-Catalyzed Transfer of Triﬂuoromethylcarbene Antonio Tinoco, Viktoria Steck, Vi DocID: 1uSIY - View Document
	New Drugs Approved in FY 2015 Review Category Approval Date No. DocID: 1r3Vv - View Document
	Microsoft Word - GILEAD BRIEFING DocID: 1r2Vm - View Document
	Treatment of Chronic Hepatitis C - January 2016 Update (The changes compared to the November 2015 Update are highlighted in yellow) Swiss Association for the Study of the Liver and Swiss Society for Infectious Diseases DocID: 1qOAQ - View Document
	Personalized Medicine Using genetic information to Help Fight Disease Personalized medicine is changing the way patients with Hepatitis C are treated…and cured.1 What is Personalized Medicine? DocID: 1qCC6 - View Document